Cardio-renal-anemia syndrome: A link between erythropoietin, dimethylarginine and homocysteine

Current Medicinal Chemistry

Volumn 19, Issue 21, 2012, Pages 3502-3507

  Righetti, M ^a  

^a Department of Anesthesia and Resuscitation   (Italy)

Author keywords

Anemia; Asymmetric dimethylarginine; Cardiovascular disease; Chronic renal failure; Erythropoiesis stimulating agents; Erythropoietin; Homocysteine

Indexed keywords

DIMETHYLARGININASE; ERYTHROPOIETIN; FOLIC ACID; HEMOGLOBIN; HOMOCYSTEINE; NITRIC OXIDE; RECOMBINANT ERYTHROPOIETIN; VITAMIN B GROUP;

ANEMIA; ARTICLE; CARDIORENAL SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DOWN REGULATION; ENDOTHELIUM; ERYTHROPOIESIS; HEART PROTECTION; HUMAN; HYPERHOMOCYSTEINEMIA; METHYLATION; NONHUMAN; PROTEIN SYNTHESIS; VITAMIN SUPPLEMENTATION;

EID: 84863749887     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712801323261     Document Type: Article

References (40)

1. Silverberg, D.S.; Wexler, D.; Iaina, A.; Schwartz, D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol, 2006, 26(4), 296-306
2. Qin, X.; Huo, Y.; Langman, C.B.; Hou, F.; Chen, Y.; Matossian, D.; Xu, X.; Wang, X. Folic acid therapy and cardiovascular disease in end-stage renal disease and advanced chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol, 2011, 6(3), 482-488
3. Righetti, M.; Ferrario, G.; Milani, S.; Serbelloni, P.; La Rosa, L.; Uccellini, M.; Sessa, A. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit, 2003, 9, PI19-PI24
4. Zoungas, S.; McGrath, B.P.; Branley, P.; Kerr, P.G.; Muske, C.; Wolfe, R.; Atkins, R.C.; Nicholls, K.; Fraenkel, M.; Hutchison, B.G.; Walker, R.; McNeil, J.J. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure. J Am Coll Cardiol, 2006, 47, 1108-1116
5. Vianna, A.C.; Mocelin, A.J.; Matsuo, T.; Morais-Filho, D.; Largura, A.; Delfino, V.A.; Soares, A.E.; Matni, A.M. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial Int, 2007, 11, 210-216
6. Jamison, R.L.; Hartigan, P.; Kaufman, J.S.; Goldfarb, D.S.; Warren, S.R.; Guarino, P.D.; Gaziano, J.M.; Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end stage renal disease: a randomized controlled trial. JAMA, 2007, 298, 1163-1170
7. Heinz, J.; Kropf, S.; Domröse, U.; Westphal, S.; Borucki, K.; Luley, C.; Neumann, K.H.; Dierkes, J.B. vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Circulation, 2010, 121, 1432-1438
8. Wrone, E.M.; Hornberger, J.M.; Zehnder, J.L.; McCann, L.M.; Coplon, N.S.; Fortmann, S.P. Randomized trial of folic acid for prevention of cardiovascular events in end stage renal disease. J Am Soc Nephrol, 2004, 15, 420-426
9. Righetti, M.; Serbelloni, P.; Milani, S.; Ferrario, G. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif, 2006, 24, 379-386
10. Righetti, M. Folic Acid and B12 Supplementation improves survival of elderly hemodialysis patients. Folic Acid: properties, medical uses and health benefits. Nova Science Publishers, Inc. Hauppauge, N Y, 2012, In Press
11. Righetti, M. Protective effect of vitamin B therapy on bone and cardiovascular disease. Recent Patents on Cardiovascular Drug Discovery, 2009, 4, 37-44
12. Righetti, M.; Ferrario, G.; Serbelloni, P.; Milani, S.; Dossi, C.; Tommasi, A. High bone and cardiovascular morbidity in folate-resistant hemodialysis patients. Nephrol Dial Transplant Plus, 2008, Vo l1 (S2), ii211 (MO002)
13. House, A.A.; Eliasziw, M.; Cattran, D.C.; Churchill, D.N.; Oliver, M.J.; Fine, A.; Dresser, G.K.; Spence, J.D. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA, 2010, 303, 1603-1609
14. Oishi, K.; Nagake, Y.; Yamasaki, H.; Fukuda, S.; Ichikawa, H.; Ota, K.; Makino, H.; Nephrol Dial Transplant, 2000, 15, 851-855
15. Grenz, A.; Hermes, M.; Hammel, P.; Roll, JB.; Osswald, H.; Kloor, D. Hyperhomo cyste in emia is associated with decreased erythropoietin expression in rats. Cell Physiol Biochem, 2010, 26, 449-456
16. Righetti, M.; Ferrario, G.; Serbelloni, P.; Milani, S.; Tommasi, A. Severe hyperhomocyste in emia improves erythropoiesis stimulating agent resistivity index in haemodialysis patients. Nephrol Dial Transplant Plus, 2010, Vol 3 (S3), iii222 (SA543)
17. Freudenthaler, S.M.; Schreeb, K.; Körner, T; Gleiter, C.H. Angiotensin II increases erythropoietin production in healthy human volunteers. Eur J Clin Invest, 1999, 29 (10), 816-23
18. Sen, U.; Herrmann, M.; Herrmann, W.; Tyagi, S.C. Synergism between AT1 receptor and hyperhomo cyste in emia during vascular remodeling. Clin Chem Lab Med, 2007, 45 (12), 1771-1776
19. Dzietko, M.; Felderhoff-Mueser, U.; Sifringer, M.; Krutz, B.; Bittigau, P.; Thor, F.; Heumann, R.; Bührer, C.; Ikonomidou, C.; Hansen, H.H. Erythropoietin protects the developing brain against N-methyl-D-aspartate receptor antagonist neurotoxicity. Neurobiol Dis, 2004, 15 (2), 177-87
20. Burdette, D.E.; Sackellares, J. C. Felbamate pharmacology and use in epilepsy. Clin Neuropharmacol, 1994, 17 (5), 389-402
21. Makhro, A.; Wang, J.; Vogel, J.; Boldyrev, A.A.; Gassmann, M.; Kaestner, L.; Bogdanova, A. Functional NMDA receptors in rat erythrocytes. Am J Physiol Cell Physiol, 2010, 296 (6), C1315-C1325
22. Thilo, F.; Liu, Y.; Krueger, K.; Foerste, N; Wittstock, A.; Scholze, A.; Tepel, M. Do cysteine residues regulates transient receptor potential canonical type 6 (TRPC6) channel protein expression? Antioxid Redox Signal, 2011, Oct 17, Epub 2011 Dec 16
23. Foller, M.; Kasinathan, R.S.; Koka, S.; Lang, C; Shumilina, E.; Birnbaumer, L.; Lang, F.; Huber, SM. TRPC6 contributes to the Ca2+ leak of human erythrocytes. Cell Physiol Biochem, 2008, 21, 183-192
24. d'Uscio, L.V; Smith, L.A.; Santhanam. A.V; Richardson, D.; Nath, K.A.; Katusic, Z.S. Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin. Hypertension, 2007, 49, 1142-1148
25. Urao, N; Okigaki, M.; Yamada, H.; Aadachi, Y; Matsuno, K.; Matsui, A.; Matsunaga, S.; Tateishi, K.; Nomura, T.; Takahashi, T.; Tatsumi, T.; Matsubara, H. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via AKT-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res, 2006, 98, 1405-1413
26. Szczech, L.; Tang, K.L.; Barnhart, H.; Sapp, S.; Wolfson, M.; Reddan, D.; CHOIR Investigators. Correction of anaemia with epoetin alpha in chronic kidney disease. New Engl J Med, 2006, 355, 2085-2089
27. Drüeke, T.B.; Locatelli, F.; Clyne, N; Eckardt, K.U.; Macdougall, I.C.; Tsakiris, D.; Burger, H.U.; Scherhag, A.; CREATE Investigators. Normalization of haemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med, 2006, 355 (20), 2071-84
28. Pfeffer, M.A.; Burdmann, E.A.; Chen, C.Y; Cooper, M.E.; de Zeeuw, D.; Eckardt, K.U.; Feyzi, J.M.; Ivanovich, P.; Kewalramani, R.; Levey, A.S.; Lewis, E.F.; McGill, J.B.; McMurray, J.J.; Parfrey, P.; Parving, H.H.; Remuzzi, G.; Singh, A.K.; Solomon, S.D.; Toto, R.; TREAT Investigators. A trial of darbepoetin alpha in type 2 diabetes and chronic kidney disease. N Engl J Med, 2009, 361 (21), 2019-32
29. Bahlmann, F.H.; Song, R.; Boehm, SM.; Mengel, M.; von Wasielewski, R.; Lindschau, C; Kirsch, T.; de Groot, K.; Laudeley, R.; Niemczyk, E.; Güler, F.; Menne, J.; Haller, H.; Fliser, D. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation, 2004, 110 (8), 1006-1012
30. Kainz, A.; Mayer, B.; Kramar, R.; Oberbauer, R. Association of ESA hypo-responsiveness and hemoglobin variability with mortality in hemodialysis patients. Nephrol Dial Transplant, 2010, 25 (11), 3701-3706
31. Abe, M.; Okada, K.; Maruyama, T; Matsumoto, K.; Soma, M. Relationship between erythropoietin responsiveness, insulin resistance, and malnutrition-inflammation-atherosclerosis (MIA) syndrome in hemodialysis patients with diabetes. Int J Artif Organs, 2011, 34 (1), 16-25
32. Maiese, K.; Li, F.; Chong, Z. New avenues of exploration for erythropoietin. JAMA, 2005, 293, 90-95
33. Wang, X.Q.; Vaziri, N.D. Erythropoietin depresses nitric oxide synthase expression by endothelial cells. Hypertension, 1999, 33, 894-899
34. Desai, A.; Zhao, Y; Lankford, H.A.; Warren. J.S. Nitric oxide suppresses EPO-induced monocyte chemoattractant protein-1 in endothelial cells: implications for atherogenesis in chronic renal disease. Lab Invest, 2006, 86, 369-379
35. Desai, A.; Zhao, Y; Warren, YS. Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice. Nephrol Dial Transplant, 2008, 23 (5), 1513-1520
36. Fliser, D. Perspectives in renal disease progression: the endothelium as a treatment target in chronic kidney disease. J Nephrol, 2010, 23 (4), 369-376
37. Ueda, S.; Yamagishi, S.; Okuda, S. New pathways to renal damage: role of ADMA in retarding renal disease progression. J Nephrol, 2010, 23 (4), 377-386
38. Ueda, S.; Yamagishi, S.; Kaida, Y.; Okuda, S. ADMA may be a missing link between chronic kidney disease and cardiovascular disease. Nephrology, 2007, 12, 582-590
39. Zoccali, C.; Kielstein, J.T. Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease? Curr Opin Nephrol Hypertens, 2006, 15, 314-320
40. Stühlinger, M.C.; Tsao, P.S.; Her, J.H.; Kimoto, M.; Balint, R.F.; Cooke, J.P. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethyl arginine. Circulation, 2001, 104, 2569-2575